We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sarepta’s Muscle-Wasting Disease Drug Sidelined by Competitor’s Trial Failure
Sarepta’s Muscle-Wasting Disease Drug Sidelined by Competitor’s Trial Failure
November 18, 2013
The FDA has delayed Sarepta Therapeutics’ NDA submission for its Duchenne muscular dystrophy (DMD) drug because of a failure in trials of a similar drug.